How should severe tricuspid regurgitation be managed, including medical therapy, diuretics, heart failure medications, anticoagulation, and criteria for referral to surgical or transcatheter valve intervention?

Management of Severe Tricuspid Regurgitation

Severe tricuspid regurgitation requires aggressive diuretic therapy as first-line treatment, with surgical intervention strongly indicated for patients undergoing left-sided valve surgery or those with symptomatic primary TR and preserved right ventricular function. 1, 2

Initial Medical Management

Loop diuretics are the cornerstone of therapy for relieving systemic and hepatic congestion, requiring aggressive titration to achieve euvolemia. 2, 3

• Add aldosterone antagonists for additional diuretic effect, particularly when hepatic congestion is present, as chronic congestion promotes secondary hyperaldosteronism. 2, 3
• Initiate guideline-directed medical therapy for heart failure with reduced ejection fraction (ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists) as first-line treatment for both primary and secondary TR. 2, 4
• Implement rhythm control strategies in patients with concurrent atrial fibrillation, as AF-induced annular remodeling is a major driver of secondary TR progression. 2
• Optimize treatment of conditions elevating left-sided filling pressures, including systemic hypertension. 1

Critical caveat: Medical therapy should not delay surgical or transcatheter referral when intervention is already indicated. 2

Surgical Intervention: Class I Indications (Strongest Recommendations)

Operate immediately in these scenarios:

• Any patient with severe TR (primary or secondary) undergoing left-sided valve surgery – this is mandatory regardless of symptoms, as concomitant repair prevents subsequent TR progression and avoids the 10-25% perioperative mortality of reoperation for isolated TR. 1, 2
• Symptomatic patients with severe primary TR without severe RV dysfunction or irreversible pulmonary hypertension – delaying surgery leads to irreversible RV damage, organ failure, and poor late surgical outcomes. 1, 2

Surgical Intervention: Class IIa Indications (Should Be Considered)

• Moderate primary TR at time of left-sided valve surgery. 1, 2
• Mild-to-moderate secondary TR with tricuspid annular dilation ≥40 mm (or ≥21 mm/m² indexed) during left-sided valve surgery – this specific threshold triggers consideration for concomitant repair, as 25% of uncorrected moderate TR progresses post-operatively. 1, 2
• Asymptomatic or minimally symptomatic severe primary TR with progressive RV dilation or deteriorating RV function – operate before irreversible RV dysfunction develops. 1, 2
• Persistent severe TR after prior left-sided valve surgery in symptomatic patients with progressive RV dilation/dysfunction, provided there is no left-sided valve dysfunction, severe biventricular dysfunction, or severe pulmonary vascular disease. 1

Surgical Technique Selection

Tricuspid valve repair with rigid or semi-rigid ring annuloplasty is the gold standard and strongly preferred over replacement when feasible, as repair provides superior post-operative outcomes. 1, 2

• Rigid/semi-rigid rings are superior to flexible bands in preventing late recurrent TR. 2
• Consider valve replacement instead of repair when: severe RV dysfunction is present, annuli are very large, significant leaflet tethering exists, or there is extensive valve destruction from carcinoid, radiation, or endocarditis. 1, 2
• When replacement is necessary, choose between mechanical and tissue valves based on individual thrombosis/anticoagulation risk versus durability considerations; meta-analyses show no survival difference. 1

Transcatheter Tricuspid Valve Intervention (TTVI)

Refer high-risk surgical patients to tertiary heart valve centers with TTVI expertise for consideration of transcatheter repair or replacement. 2, 3, 5

• TTVI is appropriate for patients with severe symptomatic TR who have prohibitive surgical risk due to severe RV dysfunction, advanced pulmonary hypertension, or significant comorbidities. 2, 3, 5
• Available transcatheter techniques include edge-to-edge repair (MitraClip), annuloplasty devices (TriCinch, Cardioband, Trialign), spacer devices (FORMA), and caval valve implantation. 6
• Early registry data show procedural success rates of approximately 62%, with 30-day mortality of 3.7% and functional improvement in 58% of patients. 6
• This should not delay referral while pursuing prolonged medical management, as missing the intervention window worsens outcomes. 3

Absolute Contraindications to Intervention

Do not operate or perform TTVI when:

• Severe irreversible RV dysfunction is present – surgery is futile with poor outcomes. 1, 2, 3, 5
• Irreversible pulmonary hypertension exists – perioperative mortality is prohibitively high. 1, 3, 5
• Irreversible liver cirrhosis from chronic hepatic congestion has developed – this is an absolute contraindication. 3

Monitoring Parameters During Medical Management

Serial transthoracic echocardiography is essential to track disease progression and intervention timing: 2, 3

• TR severity progression: vena contracta ≥7 mm, EROA ≥0.4 cm², central jet ≥50% of right atrium. 2
• Tricuspid annular diameter: progression to ≥40 mm (or ≥21 mm/m²) triggers intervention consideration if left-sided surgery becomes necessary. 1, 2
• RV function deterioration: TAPSE <17 mm or S' velocity <10 cm/s indicates worsening RV function. 2
• RV free wall longitudinal strain from 2D speckle-tracking provides more sensitive RV function assessment than TAPSE alone. 2, 3
• Pulmonary artery pressure: development of pulmonary hypertension (PASP >35-40 mmHg) changes management. 2
• Liver function tests and BNP/NT-proBNP levels as markers of hepatic congestion and disease progression. 5

Critical Pitfalls to Avoid

• Never delay addressing severe TR at the time of left-sided valve surgery – reoperation for isolated TR carries 10-25% mortality versus minimal added risk when performed concomitantly. 1, 2
• Do not use flexible annuloplasty bands when rigid/semi-rigid rings are available – flexible bands have higher recurrent TR rates. 2
• Avoid operating on patients with tricuspid annular dilation but absent or only trace TR – this provides no benefit. 2
• Do not perform aggressive diuresis causing hypotension and worsening renal function in low-output states. 3
• Recognize that functional TR does not reliably resolve after treating left-sided disease alone – traditional teaching has proven incorrect. 1, 7